Advertisement

European Journal of Clinical Pharmacology

, Volume 18, Issue 4, pp 347–350 | Cite as

Disposition of dibekacin in patients undergoing haemodialysis

  • J. A. Campillo
  • J. M. Lanao
  • A. Dominguez-Gil
  • F. Rubio
  • A. Martin
Originals

Summary

The pharmacokinetics of Dibekacin were studied in 10 patients with terminal renal impairment (creatinine clearance <5 ml/min) undergoing haemodialysis sessions lasting 4 h. The dialyzers were either the Gambro Lundia Major 13.5 or the Ultra Flo II 1.4., and the patients were divided into two groups according to the dialyzer used. Blood flow varied between 250 and 280 ml/min and dialyzate flow between 450 and 600 ml/min. All patients received a single i. v. dose of Dibekacin 1.5 mg/kg at the beginning of the dialysis session. The concentration of the antibiotic at the input and the output of the dialyzer were determined microbiologically by a plate diffusion method usingB. subtilis as the test organism. The intravenously administered antibiotic followed an open two-compartment kinetic model. The type of dialyzer used did not influence the dialysis of Dibekacin. Haemodialysis significantly increased the elimination rate of the antibiotic with respect to the interdialysis periods. The plasma half-life in the slow disposition phase fell from 30 h in the interdialysis period to 4.0 h during dialysis sessions. From the calculated pharmacokinetic parameters, a dosage regimen for this kind of patient is proposed.

Key words

dibekacin renal failure dialysis pharmacokinetics microbiological assay dosage regimen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ichikawa T, Nakano I, Hirokawa I, Okada K, Abe M, Umemura K (1973) Experimental Studies on Absorption, Excretion, Distribution and Metabolism of 3′, 4′-Dideoxy kanamycin B. III Pharmacokinetic analysis in man. Jpn J Antibiot 26: 262–266Google Scholar
  2. 2.
    Lanao JM, Dominguez-Gil A, Muriel C, Bueso J (1979) Pharmacokinetics of Dibekacin in geriatric patients. Paper presented at the 39th International Congress of Pharmaceutical Sciences, Brighton, 3–7 SeptemberGoogle Scholar
  3. 3.
    Lanao JM, Dominguez-Gil A, Tabernero JM, Sanchez-Tomero JA (1979) Pharmacokinetics of Amikacin (BBK8) in patients undergoing haemodialysis. Int J Clin Pharmacol Ther Toxicol 17: 357–360Google Scholar
  4. 4.
    Lanao JM, Dominguez-Gil A, Tabernero JM (1979) Effect of different dialyzers on the pharmacokinetics of Amikacin. Paper presented at the 1th Congres Hispano-Français de Biopharmacie et Pharmacocinetique. Barcelona, 2–6 AprilGoogle Scholar
  5. 5.
    Ueda Y, Saito A, Matsamoto F, Omori M, Shiba K, Hamaji T, Ihara H (1978) Clinical Studies on Dibekacin. Proceedings of the 10th International Congress of Chemotherapy II: 931–933Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • J. A. Campillo
    • 1
  • J. M. Lanao
    • 1
  • A. Dominguez-Gil
    • 1
  • F. Rubio
    • 2
  • A. Martin
    • 2
  1. 1.Practical Pharmacy DepartmentFaculty of PharmacySalamancaSpain
  2. 2.“Virgen de la Vega” HospitalUniversity of SalamancaSalamancaSpain

Personalised recommendations